OpenAI Acquires Biotech Data for AI Models, Sparks Crypto Debate
OpenAI is acquiring failed biotech clinical trial data to feed its AI models, creating proprietary data moats.
OpenAI is acquiring failed biotech clinical trial data to feed its AI models, creating proprietary data moats.
Layer two adoption keeps gas fees low across decentralized networks. Meanwhile MEV bots target pool liquidity amidst market shifts.
Liquidity providers face severe impermanent loss on decentralized exchanges. Smart money quiet exit signals a broader shift toward stablecoins.
Arbitrage bots extract millions from decentralized exchanges every day. Retail liquidity providers continue losing capital to toxic order flow.
Heavy whale sales of stETH eroded pool pegs during severe network congestion. Flashbots latency caused multiple liquidator bot failures.
US senators launched inquiries after model exploits hit shared software hubs. Capital continues shifting toward verifiable open networks.
AI agents already execute more daily transactions than many human traders.
DeFi protocols face heightened stress as gas fees surge across major networks. Traders push daily stablecoin volumes past twelve billion dollars.
Protocol flaws triggered millions in automated DeFi liquidations. Modern block builders face pressure from self-improving bots.
AI-driven information strategy now exploits DeFi protocols, using sybil attacks and mempool data manipulation.